IASIS PHARMA has launched a new pharmaceutical product under the brand name Venlaxin. The active ingredient of Venlaxin is venlafaxine, approved for the treatment of MajorDepressive Disorder.
Venlaxin prolonged release tablets (PR tabs) utilize a unique osmotic tablet technology to specifically address the once daily delivery of the drug. This unique osmotic tablet technology allows a high drug load and thus Venlaxin tablets are able to cover the entire dosage range up to 225 mg per day. Moreover, Venlaxin PR tablets (75mg/tab, 150mg/tab) come in a small size dosage form allowing easier swallowing and thus improved patient compliance.